Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

2023229 citationsJournal Articlegreen Open Access

Authors

Jessica C. Hassel · University Hospital Heidelberg

Sophie Piperno‐Neumann · Humboldt-Universität zu Berlin

Piotr Rutkowski · The Maria Sklodowska-Curie National Research Institute of Oncology

Jean‐François Baurain · University Hospital Heidelberg

Max Schlaak · University Hospital Heidelberg

Marcus O. Butler · Humboldt-Universität zu Berlin

Ryan J. Sullivan

Abstract

This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).

Topics & Keywords

Ocular Oncology and Treatments Immunotherapy and Immune Responses Protein Degradation and Inhibitors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 24, pp. 2256-2266

DOI: 10.1056/nejmoa2304753

Field-Weighted Citation Impact: 63.44